AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

CLARITY PHARMACEUTICALS LTD

3.160

+0.1103.61%

Volume:1.06M

Turnover:3.37M

Market Cap:1.18B

PE:-11.20

High:3.240

Open:3.170

Low:3.120

Close:3.050

52wk High:5.870

52wk Low:1.430

Shares:372.03M

Float Shares:274.26M

Volume Ratio:0.93

T/O Rate:0.39%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.282

EPS(LYR):-0.201

ROE:-53.45%

ROA:-30.54%

PB:5.05

PE(LYR):-15.69

Loading ...

Overview Company News Filings

Clarity Pharmaceuticals Ltd-Quarterly Activities/Appendix 4C Cash Flow Report

THOMSON REUTERS

Clarity Pharmaceuticals (ASX:CU6): Evaluating Valuation Following Breakthrough Co-PSMA Trial Results

Simply Wall St.

BRIEF-Clarity Signs Copper-67 Supply Agreement With Nusano

Clarity Pharmaceuticals Ltd - Copper-67 Isotope Supply Planned to Commence in Mid-2026

THOMSON REUTERS

Clarity Pharmaceuticals Ltd - Nusano Facility in Utah to Begin Operations in Late 2025

THOMSON REUTERS

BUZZ-Australia's Clarity Pharmaceuticals rises on deal with US co

Clarity Pharmaceuticals Secures Copper-67 Supply Agreement With Nusano; Shares Up 6%

MT Newswires Live

Clarity Pharmaceuticals - Co-Psma Investigator Initiated Trial Achieves Primary Endpoint

THOMSON REUTERS

Clarity Pharmaceuticals’ 64Cu-SAR-bisPSMA Outperforms Standard PSMA PET in Detecting Prostate Cancer Recurrence in Phase II Co-PSMA Trial

Clarity Pharmaceuticals Says Primary Endpoint Achieved in Prostate Cancer Imaging Trial; Shares Fall Over 6%

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/CU6.AU/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CU6.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"CU6.AU\",,,,,undefined,":{"symbol":"CU6.AU","market":"AU","secType":"STK","nameCN":"CLARITY PHARMACEUTICALS LTD","latestPrice":3.16,"timestamp":1775618478155,"preClose":3.05,"halted":0,"volume":1057286,"delay":0,"changeRate":0.03606557377049191,"nameEN":"CLARITY PHARMACEUTICALS LTD","floatShares":274264090,"shares":372030071,"eps":-0.282253,"marketStatus":"Trading","change":0.11,"latestTime":"04-08 13:21:24 AEST","open":3.17,"high":3.24,"low":3.12,"amount":3368525,"amplitude":0.039344,"askPrice":3.16,"askSize":4144,"bidPrice":3.15,"bidSize":8242,"shortable":3,"etf":0,"ttmEps":-0.282253,"tradingStatus":2,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1775628000000},"marketStatusCode":2,"adr":0,"exchange":"ASX","adjPreClose":3.05,"openAndCloseTimeList":[[1775606400000,1775628000000]],"volumeRatio":0.928249,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"CU6.AU","preClose":3.05,"auctionPrice":3.17,"auctionVolume":46525,"auctionTime":1775606345846,"referenceTime":1775557803089,"auction":1,"marketStatus":"盘前竞价","timestamp":1775606345846}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"CU6.AU\",,,,,undefined,":{"symbol":"CU6.AU","floatShares":274264090,"roa":"-30.54%","roe":"-53.45%","lyrEps":-0.201427,"volumeRatio":0.928249,"shares":372030071,"dividePrice":0,"high":3.24,"amplitude":0.039344,"preClose":3.05,"low":3.12,"week52Low":1.43,"pbRate":"5.05","psRate":"111.12","week52High":5.87,"institutionHeld":0,"latestPrice":3.16,"committee":0.330857,"eps":-0.282253,"divideRate":0,"volume":1057286,"delay":0,"ttmEps":-0.282253,"open":3.17,"prevYearClose":3.38,"prevWeekClose":3.15,"prevMonthClose":3.1,"prevQuarterClose":3.1,"fiveDayClose":3.03,"twentyDayClose":3.29,"sixtyDayClose":3.8,"dividendGrowthYears":0,"fiveYearAvgDividendRate":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CU6.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CU6.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CU6.AU\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2579909104","title":"Clarity Pharmaceuticals Ltd-Quarterly Activities/Appendix 4C Cash Flow Report","url":"https://stock-news.laohu8.com/highlight/detail?id=2579909104","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579909104?lang=en_us&edition=fundamental","pubTime":"2025-10-31 07:10","pubTimestamp":1761865806,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251030:nTUE58FH2B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CU6.AU","BK7096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2576051085","title":"Clarity Pharmaceuticals (ASX:CU6): Evaluating Valuation Following Breakthrough Co-PSMA Trial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2576051085","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576051085?lang=en_us&edition=fundamental","pubTime":"2025-10-17 19:16","pubTimestamp":1760699766,"startTime":"0","endTime":"0","summary":"Clarity Pharmaceuticals (ASX:CU6) has reported that its Co-PSMA trial achieved a key milestone, showing that 64Cu-SAR-bisPSMA identifies significantly more prostate cancer lesions compared to current standard imaging in patients with low PSA levels.\nSee our latest analysis for Clarity Pharmaceuticals.\nClarity’s latest clinical achievement has reignited interest, helping the stock stage a strong rebound. The 30-day share price return sits at an impressive 41.0%, though shares are still down...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-cu6/clarity-pharmaceuticals-shares/news/clarity-pharmaceuticals-asxcu6-evaluating-valuation-followin","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-cu6/clarity-pharmaceuticals-shares/news/clarity-pharmaceuticals-asxcu6-evaluating-valuation-followin","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["CU6.AU","BK7096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2575416827","title":"BRIEF-Clarity Signs Copper-67 Supply Agreement With Nusano","url":"https://stock-news.laohu8.com/highlight/detail?id=2575416827","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575416827?lang=en_us&edition=fundamental","pubTime":"2025-10-16 21:06","pubTimestamp":1760619998,"startTime":"0","endTime":"0","summary":"BRIEF-Clarity Signs Copper-67 Supply Agreement With NusanoOct 16 (Reuters) - Clarity Pharmaceuticals Ltd CU6.AX:CLARITY SIGNS COPPER-67 SUPPLY AGREEMENT WITH NUSANOCLARITY PHARMACEUTICALS LTD - NUSANO","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251016:nTUAB2XRRR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CU6.AU","BK7096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2575653741","title":"Clarity Pharmaceuticals Ltd - Copper-67 Isotope Supply Planned to Commence in Mid-2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2575653741","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575653741?lang=en_us&edition=fundamental","pubTime":"2025-10-16 21:04","pubTimestamp":1760619847,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251016:nTUAB2XRRR:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CU6.AU","BK7096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2575413687","title":"Clarity Pharmaceuticals Ltd - Nusano Facility in Utah to Begin Operations in Late 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2575413687","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575413687?lang=en_us&edition=fundamental","pubTime":"2025-10-16 21:04","pubTimestamp":1760619847,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251016:nTUAB2XRRR:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CU6.AU","BK7096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2575795089","title":"BUZZ-Australia's Clarity Pharmaceuticals rises on deal with US co","url":"https://stock-news.laohu8.com/highlight/detail?id=2575795089","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575795089?lang=en_us&edition=fundamental","pubTime":"2025-10-16 12:59","pubTimestamp":1760590760,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Clarity Pharmaceuticals rises on deal with US co** Clarity Pharmaceuticals CU6.AX jumps as much as ~15% to A$5.25; marks biggest intraday pct rise since October 3** Clinical radio-pharmaceutical co signs copper-67 supply agreement with California-based Nusano** Nusano to supply therapeutic isotope for co's clinical trials, commercial use** YTD, CU6 gains 23.7%  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251016:nL6N3VX0A1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","CU6.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2575058766","title":"Clarity Pharmaceuticals Secures Copper-67 Supply Agreement With Nusano; Shares Up 6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2575058766","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575058766?lang=en_us&edition=fundamental","pubTime":"2025-10-16 08:55","pubTimestamp":1760576153,"startTime":"0","endTime":"0","summary":"Clarity Pharmaceuticals  entered into an agreement for Nusano to supply copper-67, a critical therapeutic isotope used in cancer treatments, according to a Thursday filing with the Australian bourse.Nusano's 190,000-square-foot facility in Utah is set to start operations later this year, with copper-67 supply expected by mid-2026, using proprietary accelerator technology and in-house isotope production to deliver a reliable and scalable domestic supply, the filing said.The agreement has an initial three-year term starting Thursday, with automatic two-year renewals and standard industry cancellation provisions, the filing added.Clarity Pharmaceuticals' shares rose almost 6% in recent Thursday trade.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CU6.AU","QCmain","BK7096","MHGmain"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2575152232","title":"Clarity Pharmaceuticals - Co-Psma Investigator Initiated Trial Achieves Primary Endpoint","url":"https://stock-news.laohu8.com/highlight/detail?id=2575152232","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575152232?lang=en_us&edition=fundamental","pubTime":"2025-10-14 21:22","pubTimestamp":1760448125,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251014:nFWN3VV1FZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","CU6.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2575921308","title":"Clarity Pharmaceuticals’ 64Cu-SAR-bisPSMA Outperforms Standard PSMA PET in Detecting Prostate Cancer Recurrence in Phase II Co-PSMA Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2575921308","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575921308?lang=en_us&edition=fundamental","pubTime":"2025-10-14 21:04","pubTimestamp":1760447080,"startTime":"0","endTime":"0","summary":"Clarity Pharmaceuticals' 64Cu-SAR-bisPSMA Outperforms Standard PSMA PET in Detecting Prostate Cancer Recurrence in Phase II Co-PSMA Trial. Clarity Pharmaceuticals Ltd. announced that its Co-PSMA  Investigator-Initiated Trial, led by Professor Louise Emmett at St Vincent's Hospital Sydney, has achieved its primary endpoint. The Phase II trial evaluated the diagnostic performance of 64Cu-SAR-bisPSMA compared to the standard-of-care 68Ga-PSMA-11 PET/CT in detecting PSMA-positive prostate cancer lesions in patients with low prostate-specific antigen  levels following radical prostatectomy. Results showed a statistically significant higher number of lesions detected using 64Cu-SAR-bisPSMA. The findings support ongoing development of 64Cu-SAR-bisPSMA, with further clinical trials planned, including the CLARIFY and AMPLIFY Phase III studies. The results of the Co-PSMA trial have already been presented.Disclaimer: This news brief was created by Public Technologies  using generative artificial ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251014:nNDL51XNz3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CU6.AU","BK7096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2575253588","title":"Clarity Pharmaceuticals Says Primary Endpoint Achieved in Prostate Cancer Imaging Trial; Shares Fall Over 6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2575253588","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575253588?lang=en_us&edition=fundamental","pubTime":"2025-10-14 09:51","pubTimestamp":1760406677,"startTime":"0","endTime":"0","summary":"Clarity Pharmaceuticals (ASX:CU6) said its Co-PSMA phase two investigator-initiated trial achieved its primary endpoint with a statistically significant higher number of prostate-specific membrane ant","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7096","CU6.AU"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":3,"totalSize":50,"code":"91000000","status":"200"}]}}